

Decree of the Ministry of Social Affairs and Health

on fees chargeable by the Finnish Medicines Agency

In accordance with Decision of the Ministry of Social Affairs and Health, the following is enacted under section 8 of the Act on Criteria for Charges Payable to the State (150/1992), as amended by Act 348/1994:

Section 1

Performances chargeable under public law

Performances chargeable under public law as defined in section 6 of the Act on Criteria for Charges Payable to the State (150/1992), for which the Finnish Medicines Agency charges fixed fees that correspond to the average costs of the performances as specified in the enclosed table of fees, include the following:

- 1) marketing authorisations, registrations and special licences for medicinal products;
- 2) variations and other performances pertaining to medicinal products;
- 3) other authorisations, decisions, certificates and notifications related to pharmacovigilance;
- 4) scientific advice;
- 5) inspections related to the conduct of operations;
- 6) processing the application for approval of an authorised test laboratory as referred to in section 24 of the Chemicals Act (599/2013);
- 7) authorisation required under section 20b of the Act on the Medical Use of Human Organs and Tissues (101/2001), as well as the documents required under section 23a;
- 8) authorisation required under section 4 of the Blood Service Act (197/2005) as well as the authorisation required under section 22 for the import of blood or its components from third countries;
- 9) copies replacing the original decisions or corresponding documents kept at the Finnish Medicines Agency;
- 10) decisions concerning access to documents other than those under sections 9 and 11 of the Act on the Openness of Government Activities (621/1999).
- 11) statements given for the assessment and follow-up of agreements concerning the conditional reimbursement status pursuant to Chapter 6, section 6a of the Health Insurance Act (1224/2004).

The fee charged for a performance referred to in section 1 or 2 of the Annex or the special authorisation fee referred to in section 4 may be waived if the demand for the medicinal product is negligible, but the medicinal product concerned must be deemed essential for treatment.

Section 2

Performances free of charge

No fee shall be charged for:

1) processing and reviewing a notification relating to clinical trials on medicinal products in human subjects or clinical trials on veterinary medicinal products in animals conducted by an individual investigator, a trial group, a university department, a university hospital clinic, a university veterinary hospital or the National Institute for Health and Welfare if the trial has no outside financing or is financed by a non-profit organisation;

2) narcotics licences needed for animal experiments authorised by the Animal Experiment Board;

3) narcotics licences needed by the police, customs authorities or customs laboratories engaged in official duties, or for decisions concerning the classification of medicinal products.

In cases set out above in paragraph 1 of subsection 1, the trial notification must be accompanied by a statement to the effect that the trial will not receive any outside financing, or that outside financing will be provided by a non-profit organisation. Medicinal products received free of charge for the purpose of the trial are not considered as outside financing.

Section 3

Charging of the fee in certain situations

The fee referred to in section 1(1) above shall also be charged if a negative decision is given on the application referred to therein.

Section 4

Performances priced according to commercial criteria

Other performances within the meaning of section 7 of the Act on Criteria for Charges Payable to the State, which the Finnish Medicines Agency shall price according to commercial criteria, include the following:

1) information services relating to data and information systems, except for minor guidance and advice;

2) training and consultation services;

3) specially ordered reports, investigations, inspections and analyses;

4) publications;

5) copies;

6) use of the premises occupied by the agency and agency services;

7) special services and performances ordered by clients other than, but comparable to, those referred to in points 1–5 above.

Section 5

Other fees

The fees charged for information retrieval referred to in section 34(2) of the Act on the Openness of Government Activities, and for providing copies and printouts, as defined in section 34(3) of said act, shall be decided by the Finnish Medicines Agency, with due regard to the provisions of section 34 of the Act on the Openness of Government Activities.

Section 6

Entry into force

This Decree shall enter into force on 1 May 2019 and will remain in force until 31 March 2020.

For performances concerning matters filed prior to the entry into force of this Decree, a fee shall be charged in accordance with the provisions that were in force upon entry into force of this Decree.

Helsinki, 15 April 2018

Minister of Social Affairs and Health Pirkko Mattila

Ministerial Counsellor Anne Ilkka

1 MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.1 MARKETING AUTHORISATION AND REGISTRATION APPLICATIONS FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.1.1 National marketing authorisation and registration procedure for medicinal products intended for human use: application-specific basic fee	
<ul style="list-style-type: none"> ▪ New active substance / known active substance (Dir. 2001/83/EC, Article 8) ▪ Applications based on established medicinal use (Dir. 2001/83/EC, Article 10 (a)) ▪ Combination products (Dir. 2001/83/EC, Article 10(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/83/EC, Article 10.4) ▪ Homeopathic products subject to marketing authorisation for which a medicinal purpose is stated (Dir. 2001/83/EC, Article 16) 	
For the first marketing authorisation applied for	€3,000
Subsequent pharmaceutical forms or strengths	€8,000
<ul style="list-style-type: none"> ▪ Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/83/EC, Article 10c) ▪ Generic products (Dir. 2001/83/EC, Article 10.1) ▪ Abridged applications of mixed type (Dir. 2001/83/EC, Article 10.3) 	
For each marketing authorisation or registration applied for	€8,000
<ul style="list-style-type: none"> ▪ Traditional herbal medicinal products to be registered (Dir. 2004/24/EC) ▪ Herbal medicinal products subject to marketing authorisation for which a community monograph exists (Dir. 2004/27/EC, Article 10a) 	
For each marketing authorisation or registration applied for	€6,000

<ul style="list-style-type: none"> ▪ Extensions to a marketing authorisation and registration (Commission Regulation (EC) No 1234/2008) <p>For each marketing authorisation or registration applied for</p>	€8,000
<ul style="list-style-type: none"> ▪ Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/83/EC, Article 16) <p>For each marketing authorisation or registration applied for</p>	€2,100
<ul style="list-style-type: none"> ▪ Homeopathic products subject to registration, including registration extensions (Dir. 2001/83/EC, Article 14) <p>Products containing 1 to 5 stock substances</p> <p>Products containing more than 5 stock substances</p>	<p>€50</p> <p>€1,200</p>

1.1.2 Mutual recognition procedure or decentralised procedure for medicinal products intended for human use, Finland as a Concerned Member State: application-specific basic fee	
<ul style="list-style-type: none"> ▪ New active substance / known active substance (Dir. 2001/83/EC, Article 8) ▪ Applications based on established medicinal use (Dir. 2001/83/EC, Article 10 (a)) ▪ Combination products (Dir. 2001/83/EC, Article 10(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/83/EC, Article 10.4) ▪ Homeopathic products subject to marketing authorisation for which a medicinal purpose is stated (Dir. 2001/83/EC, Article 16) <p>For the first marketing authorisation applied for</p> <p>Subsequent pharmaceutical forms or strengths</p>	<p>€10,000</p> <p>€6,000</p>
<ul style="list-style-type: none"> ▪ Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/83/EC, Article 10c) ▪ Generic products 	

<p>(Dir. 2001/83/EC, Article 10.1)</p> <ul style="list-style-type: none"> ▪ Abridged applications of mixed type (Dir. 2001/83/EC, Article 10.3) <p>For each marketing authorisation or registration applied for</p>	€6,000
<ul style="list-style-type: none"> ▪ Traditional herbal medicinal products to be registered (Dir. 2004/24/EC) ▪ Herbal medicinal products subject to marketing authorisation for which a community monograph exists (Dir. 2004/27/EC, Article 10a) <p>For each marketing authorisation or registration applied for</p>	€6,000
<ul style="list-style-type: none"> ▪ Extensions to a marketing authorisation and registration (Commission Regulation (EC) No 1234/2008) <p>For each marketing authorisation or registration applied for</p>	€6,000
<ul style="list-style-type: none"> ▪ Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/83/EC, Article 16) <p>For each marketing authorisation or registration applied for</p>	€2,100
<ul style="list-style-type: none"> ▪ Homeopathic products subject to registration, including registration extensions (Dir. 2001/83/EC, Article 14) <p>Products containing 1 to 5 stock substances</p> <p>Products containing more than 5 stock substances</p>	<p>€950</p> <p>€1,200</p>
<p>1.1.3 Mutual recognition procedure or decentralised procedure for medicinal products intended for human use, Finland as a Reference Member State: process fee</p>	
<p>Process fee for a mutual recognition procedure</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	€12,000

<p>Process fee for a decentralised procedure</p> <p>In addition to the process fee, a basic fee according to section 1.1.1 (National marketing authorisation and registration procedure for medicinal products intended for human use) for each marketing authorisation or registration applied for.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p> <p>The process fee and application fee will be charged when the application has been accepted for processing.</p>	<p>€12,000</p>
---	-----------------------

1.1.4 Marketing authorisation for medicinal products intended for human use, parallel import	
For the first country of acquisition	€1,900
For each subsequent country of acquisition	€1,100

1.2 VARIATION APPLICATIONS FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

The fees specified below will be charged separately for each marketing authorisation and registration. If the same variation of other pharmaceutical forms and/or strengths of the same trade name is being applied for in one application, the fee will only be charged for one marketing authorisation or registration

In the grouping of the variations (G), the processing fee pursuant to the Decree will be payable for each variation. This does not apply to a grouped application for variations concerning the trade name, for which the processing fee will only be charged one.

In the worksharing procedure (WS), the processing fee pursuant to the Decree is payable for each variation applied for. The processing fee is payable depending on Finland's role in the process concerned.

1.2.1 National marketing authorisation or registration of medicinal products intended for human use: processing fee	
Type II variations (Commission Regulation (EC) No 1234/2008) Addition to therapeutic indication	€1,000
Other type II variations	€1,000
Type IB variations	€130
1.2.2 Mutual recognition procedure for medicinal products intended for human use, Finland as a Concerned Member State: processing fee	
Type II variations (Commission Regulation (EC) No 1234/2008) Addition to therapeutic indication	€3,000
Other type II variations	€800
Type IB variations	€340
1.2.3 Mutual recognition procedure for medicinal products intended for human use, Finland as Reference Member State: process fee	
Type II variations (Commission Regulation (EC) No 1234/2008) Process fee Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products intended for human use)	€2,000
Type IB variations Process fee Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products intended for human use)	€900
Type IA variations Process fee For grouped variation applications, the process fee is only paid once based on the most significant variation (II/IB/IA). An exception to the above are type IA grouped variation applications that include several processes.	€500
Type IA grouped variation applications including more than one process (FI/H/XXXX/IA/G)	

Process fee	€1,000
Worksharing procedure	
Process fee	€4,000
Additionally, a processing fee in accordance with section 1.2.1 (National marketing authorisation or registration of medicinal products intended for human use)	

1.2.4 Parallel import of medicinal products intended for human use	
Type II variations (Commission Regulation (EC) No 1234/2008)	€600
Type IB variations	€250

1.2.5 Transfer of marketing authorisation or registration of medicinal products intended for human use to a new holder	
Transfer of a marketing authorisation or registration to another holder	€200

1.3 ANNUAL FEES FOR MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

<ul style="list-style-type: none"> ▪ The fee is charged for each marketing authorisation and registration. ▪ The annual fee includes the cost of register maintenance, medical information produced by the Finnish Medicines Agency, adverse effect monitoring with the associated PSURs, processing of product defects, marketing authorisation or registration renewal, processing of Type IA applications, monitoring of medicinal product advertising, maintenance of ATC classification and dose registers (DDD), and medicine consumption statistics. ▪ The fee is determined according to the average costs arising from the performance of above-mentioned duties for each marketing authorisation or registration. 	
Medicinal products referred to in sections 21–21c and 21e of the Medicines Act	€1,400
Parallel import products	€680
Registered traditional herbal medicinal products	€200

Herbal medicinal products, homeopathic and anthroposophic products subject to marketing authorisation	€200
Registered homeopathic and anthroposophic products	€200

1.4 RENEWAL OF A MARKETING AUTHORISATION OF MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.4.1 Mutual recognition procedure for medicinal products intended for human use, Finland as Reference Member State: process fee	
<p>A process fee is payable for renewal when Finland acts as a Reference Member State in the mutual recognition procedure.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	
Renewal process fee	€2,000
Renewal process fee, abridged renewal application	€1,000

1.5 APPLICATION FOR WAIVER OF THE MARKETING AUTHORISATION AND REGISTRATION OF MEDICINAL PRODUCTS INTENDED FOR HUMAN USE

1.5.1 Application for waiver of the marketing authorisation or registration of medicinal products under section 29(3) of the Medicines Act	
<p>Application for waiver (sunset clause)</p> <p>The fee includes all pharmaceutical forms and/or strengths of the same trade name.</p>	€100

2 VETERINARY MEDICINAL PRODUCTS

2.1 MARKETING AUTHORISATION AND REGISTRATION APPLICATIONS FOR VETERINARY MEDICINAL PRODUCTS

2.1.1 National marketing authorisation and registration procedure for veterinary medicinal products: application-specific basic fee	
<ul style="list-style-type: none"> ▪ New active substance / known active substance (Dir. 2001/82/EC, Article 12) ▪ Applications based on established medicinal use (Dir. 2001/82/EC, Article 13 (a)) ▪ Combination products (Dir. 2001/82/EC, Article 13(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/82/EC, Article 13.4) 	
For the first marketing authorisation applied for	€9,750
Subsequent pharmaceutical forms or strengths	€6,000
<ul style="list-style-type: none"> ▪ Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/82/EC, Article 13c) ▪ Generic products (Dir. 2001/82/EC, Article 13.3) ▪ Abridged applications of mixed type (Dir. 2001/82/EC, Article 13.3) 	
For each marketing authorisation or registration applied for	€6,000
<ul style="list-style-type: none"> ▪ Extensions to a marketing authorisation (Commission Regulation (EC) No 1234/2008) 	
For each marketing authorisation or registration applied for	€6,000
<ul style="list-style-type: none"> ▪ Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/82/EC, Article 19) 	
For each marketing authorisation or registration applied for	€1,680
<ul style="list-style-type: none"> ▪ Homeopathic products subject to registration, including registration extensions 	

(Dir. 2001/82/EC, Article 17)	
Products containing 1 to 5 stock substances	€850
Products containing more than 5 stock substances	€1,100

2.1.2 Mutual recognition procedure or decentralised procedure for veterinary medicinal products, Finland as a Concerned Member State: application-specific basic fee	
<ul style="list-style-type: none"> ▪ New active substance / known active substance (Dir. 2001/82/EC, Article 12) ▪ Applications based on established medicinal use (Dir. 2001/82/EC, Article 13 (a)) ▪ Combination products (Dir. 2001/82/EC, Article 13(b)) ▪ Applications for similar biological medicinal products (Dir. 2001/82/EC, Article 13.4) 	
For the first marketing authorisation applied for	€9,500
Subsequent pharmaceutical forms or strengths	€4,500
<ul style="list-style-type: none"> ▪ Applications where the applicant has obtained the consent of the original marketing authorisation holder to refer to the marketing authorisation documentation (Dir. 2001/82/EC, Article 13c) ▪ Generic products (Dir. 2001/82/EC, Article 13.3) ▪ Abridged applications of mixed type (Dir. 2001/82/EC, Article 13.3) 	
For each marketing authorisation applied for	€4,500
<ul style="list-style-type: none"> ▪ Extensions to a marketing authorisation (Commission Regulation (EC) No 1234/2008) 	
For each marketing authorisation applied for	€4,500
<ul style="list-style-type: none"> ▪ Homeopathic products subject to marketing authorisation for which no medicinal purpose is stated, including marketing authorisation extensions (Dir. 2001/82/EC, Article 19) 	
For each marketing authorisation or registration applied for	€1,680

<ul style="list-style-type: none"> ▪ Homeopathic products subject to registration, including registration extensions (Dir. 2001/82/EC, Article 17) 	
Products containing 1 to 5 stock substances	€850
Products containing more than 5 stock substances	€1,100

2.1.3 Mutual recognition procedure or decentralised procedure for veterinary medicinal products, Finland as a Reference Member State: process fee	
Process fee for a mutual recognition procedure The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.	€12,000
Process fee for a decentralised procedure In addition to the process fee, a basic fee according to section 2.1.1 (National marketing authorisation or registration procedure for veterinary medicinal products) for each marketing authorisation or registration. The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately. The process fee and application fee will be charged when the application has been accepted for processing.	€12,000

2.1.4 Marketing authorisation for veterinary medicinal products, parallel import	
For the first country of acquisition	€1,900
For each subsequent country of acquisition	€1,100

2.2 VARIATION APPLICATIONS FOR VETERINARY MEDICINAL PRODUCTS

The fees specified below will be charged separately for each marketing authorisation and registration. If the same variation of other pharmaceutical forms and/or strengths of the same trade name is being applied for in one application, the fee will only be charged for one marketing authorisation or registration

In the grouping of the variations (G), the processing fee pursuant to the Decree will be payable for each variation. This does not apply to a grouped application for variations concerning the trade name, for which the processing fee will only be charged one.
In the worksharing procedure (WS), the processing fee pursuant to the Decree is payable for each variation applied for. The processing fee is payable depending on Finland's role in the process concerned.

2.2.1 National marketing authorisation or registration of veterinary medicinal products: processing fee	
Type II variations (Commission Regulation (EC) No 1234/2008)	
Addition to therapeutic indication and variation to withdrawal period	€3,750
Other type II variations	€800
Type IB variations	€340

2.2.2 Mutual recognition procedure for veterinary medicinal products, Finland as a Concerned Member State	
Type II variations (Commission Regulation (EC) No 1234/2008)	
Addition to therapeutic indication or variation to withdrawal period	€3,000
Other type II variations	€600
Type IB variations	€250

2.2.3 Mutual recognition procedure for veterinary medicinal products, Finland as Reference Member State: process fee	
Type II variations (Commission Regulation (EC) No 1234/2008)	
Process fee	€2,000
Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation or registration of veterinary medicinal products)	
Type IB variations	
Process fee	€900
Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation or registration of veterinary medicinal products)	
Type IA variations	

<p>Process fee</p> <p>For grouped variation applications, the process fee is only paid once based on the most significant variation. An exception to the above are type IA grouped variation applications that include several processes.</p> <p>Type IA grouped variation applications including more than one process (FI/V/XXXX/IA/G) Process fee</p> <p>Worksharing procedure Process fee Additionally, a processing fee in accordance with section 2.2.1 (National marketing authorisation or registration of veterinary medicinal products).</p>	<p>€500</p> <p>€500</p> <p>€4,000</p>
--	--

2.2.4 Transfers of marketing authorisation or registration of veterinary medicinal products to a new holder	
Transfer of a marketing authorisation or registration to another holder	€200

2.2.5 Parallel import of veterinary medicinal products	
Type II variations (Commission Regulation (EC) No 1234/2008)	€600
Type IB variations	€250

2.3 ANNUAL FEES FOR VETERINARY MEDICINAL PRODUCTS

<ul style="list-style-type: none"> ▪ The fee is charged for each marketing authorisation and registration. ▪ The annual fee includes the cost of register maintenance, medical information produced by the Finnish Medicines Agency, adverse effect monitoring with the associated PSURs, processing of product defects, marketing authorisation or registration renewal, processing of Type IA applications, monitoring of medicinal product advertising, maintenance of ATC classification and dose registers (DDD), and medicine consumption statistics. ▪ The fee is determined according to the average costs arising from the performance of above-mentioned duties for each marketing authorisation or registration. <p>Veterinary medicinal products referred to in sections 21–21c and 21e of the Medicines Act</p>	<p>€1,400</p>
--	----------------------

Homeopathic and anthroposophic products registered for veterinary use and subject to marketing authorisation	€200
---	-------------

2.4 RENEWAL OF MARKETING AUTHORISATIONS FOR VETERINARY MEDICINAL PRODUCTS

2.4.1 Mutual recognition procedure for veterinary medicinal products, Finland as Reference Member State: process fee	
<p>A process fee is payable for renewal when Finland acts as a Reference Member State in the mutual recognition procedure.</p> <p>The process fee includes all pharmaceutical forms and/or strengths of the same trade name. The fee is charged for each process separately.</p>	
Renewal process fee	€2,000
Renewal process fee, abridged renewal application	€1,000

2.5 APPLICATION FOR WAIVER OF THE MARKETING AUTHORISATION AND REGISTRATION OF VETERINARY MEDICINAL PRODUCTS UNDER SECTION 29(3) OF THE MEDICINES ACT

2.5.1 Application for waiver of the marketing authorisation or registration of medicinal products under section 29(3) of the Medicines Act	
<p>Application for waiver (sunset clause)</p> <p>The fee includes all pharmaceutical forms and/or strengths of the same trade name.</p>	€100

3 SCIENTIFIC ADVICE

Scientific advice on medicinal products intended for human use	€5,000
Scientific advice on medicinal products intended for veterinary use	€750

4 SPECIAL AUTHORISATIONS AND CLASSIFICATION

Authorisation (special authorisation) referred to in section 21f of the Medicines Act	€20
Special authorisations requiring urgent processing	€40
Product classification decisions	€500

5 EXPORT CERTIFICATES

Certificates concerning the export, industrial manufacture and wholesale of medicines	€70
--	------------

6 OTHER AUTHORISATIONS, DECISIONS, CERTIFICATES AND NOTIFICATIONS RELATED TO PHARMACOVIGILANCE

Processing of notifications related to clinical trials	€3,000
Processing of notifications related to veterinary clinical trials	€750
Processing of authorisations related to clinical trials	€3,300

Licences concerning the industrial manufacture of medicinal products, pharmaceutical wholesaling and industrial manufacture of advanced therapy medicinal product, registration concerning the distribution of medicinal products, and changes to licences and registrations:	
Licence for the industrial manufacture of medicinal products	€3,000
Licence for the contract analysis of medicinal products	€1,500
Licence for the manufacture of medicinal products for clinical trials	€1,500
Manufacturing authorisation of advanced therapy medicinal products	€1,500
Pharmaceutical wholesale licence	€1,750
Pharmaceutical wholesale licence for anthroposophic and homeopathic products	€1,000
Registration of a distributor of medicinal products	€1,000
If the application for an operating licence or for changes to an operating licence requires pre-inspection, the inspection will be subject to a separate charge.	
Operating licences for tissue or blood service operations and changes to them	€3,000
Import and export licences related to tissue or blood service operations	€500
Import certificate related to tissue operations	€500
Patient-specific import and export licences	€100
If the application for an operating licence or for changes to an operating licence requires pre-inspection, the inspection will be subject to a separate charge.	
Pharmacy licence	€5,000
Pharmacy service point licence	€1,250
Running a pharmacy service point as a precondition for a pharmacy licence	€1,250
Short-term pharmacy service point licence (duration less than 1 month)	€500
Subsidiary pharmacy authorisation	€2,500

Running a subsidiary pharmacy as a precondition for a pharmacy licence	€2,500
Changing the location area of a subsidiary pharmacy at the subsidiary pharmacy authorisation holder's request	€2,500
Processing of a pharmacy online service notification	€1,000
Processing of an application for the use of a new means of distance communication by the pharmacy	€200
Extension of the time limit granted for pharmacy business	€1,000
Granting a pharmacy licence pursuant to section 54(2) of the Medicines Act	€5,000
Authorisation for setting up a hospital pharmacy, dispensary or military pharmacy	€5,000
Licence for non-industrial manufacture under section 12a of the Medicines Act	€2,000
Authorisation referred to in section 62 of the Medicines Act to supply medicinal products, except for the supply of medicines for the treatment of an individual patient or for the supply of vaccines for the prevention of communicable diseases under the Communicable Diseases Act	€1,000
A licence to store less medicines than the statutory minimum or to store medicinal substances instead of medicinal products, for each product applied for	
Application filed at least 2 weeks prior to the date of commencement of the underrun or replacement applied for	€600
Application filed less than 2 weeks prior to the date of commencement of the underrun or replacement applied for	€1,200
Exemption from maintaining obligatory reserve supplies of medicinal products or alternate way of maintaining obligatory reserve supplies; as a whole or for each group of medicinal products containing the same medicinal substance	
Application filed at least 2 weeks prior to the date of commencement of the exemption or alternative arrangement applied for	€600

Application filed less than 2 weeks prior to the date of commencement of the exemption or alternative arrangement applied for	€1,200
<p>Licences and decisions in accordance with narcotics legislation including decisions on the registration concerning the conduct of operations, decisions relating to persons in charge, and licences concerning substances used in drug manufacturing with the exception of licences needed for the treatment of an individual patient</p> <p>Certificates of free sale for medicines, narcotics or narcotics precursors for import required by other countries and the registration of precursor users as specified in Article 3 of Regulation (EC) 273/2004.</p>	<p>€200</p> <p>€100</p>
Decision concerning approval of a GLP testing laboratory and changes to the decision	€1,000

7 INSPECTIONS RELATED TO THE CONDUCT OF OPERATIONS

In inspections carried out abroad, the fee for additional days will be charged for each inspector, and in addition to the inspection fee, the actual travel and accommodation costs as well as potential interpretation costs will be charged.

<p>Inspections related to clinical trials, domestic For 1 day €1,000 Additional days €2,000</p> <p>Inspections related to clinical trials, abroad For 1 day €1,000 Additional days for each inspector €2,000</p> <p>Additionally, the actual travel costs will be charged for all inspections carried out abroad.</p>	
---	--

<p>Inspection of a marketing authorisation holder of a medicinal product and a registration holder of traditional herbal medicinal product, domestic For 1 day Additional days</p> <p>Inspection of a marketing authorisation holder of a medicinal product and a registration holder of traditional herbal medicinal product, abroad For 1 day Additional days for each inspector</p>	<p>€4,000 €2,000</p> <p>€4,000 €2,000</p>
<p>Inspection of a pharmaceutical or excipient manufacturer, domestic For 1 day Additional days Inspection of a pharmaceutical manufacturer based on documents</p> <p>Inspection of a pharmaceutical or excipient manufacturer, abroad For 1 day Additional days for each inspector</p> <p>Inspection of a pharmaceutical or excipient manufacturer at the operator's request, abroad For 1 day Additional days for each inspector</p> <p>Additionally, the actual travel costs will be charged for all inspections carried out abroad.</p>	<p>€6,000 €3,000 €2,500</p> <p>€6,000 €3,000</p> <p>€10,000 €5,000</p>
<p>Inspection of a unit manufacturing medicinal products for clinical trials and a laboratory engaged in contract analysis, domestic For 1 day Additional days</p> <p>Inspection of a unit manufacturing medicinal products for clinical trials and a laboratory engaged in contract analysis, abroad For 1 day Additional days for each inspector</p> <p>Additionally, the actual travel costs will be charged for all inspections carried out abroad.</p>	<p>€3,000 €1,500</p> <p>€6,000 €3,000</p>

Inspection of a pharmaceutical wholesaler that engages in distribution to retail distributors For 1 day Additional days Inspection based on documents	€6,000 €3,000 €2,000
Inspection of a pharmaceutical wholesaler that does not engage in distribution to retail distributors For 1 day Additional days Inspection based on documents	€4,000 €2,000 €2,000
Inspection of an anthroposophic or homeopathic product wholesaler or inspection of a medicinal product distributor For 1 day Additional days Inspection based on documents	€2,000 €1,000 €1,000
Inspection of blood service and tissue establishment operations and an organ transplantation centre For 1 day Additional days Inspection of blood service or tissue establishment operations targeted at a single area of operations with duration of not more than 4 hours Inspection of tissue establishment operations based on documents	€3,000 €1,500 €2,000 €1,000
Inspection of an organ donation hospital	€2,000
Inspection of an organ donation hospital based on documents	€1,000
Inspection related to the manufacturing authorisation of an advanced therapy medicinal product manufactured under a national manufacturing authorisation For 1 day Additional days	€3,000 €1,500

<p>Inspection of a pharmacy, hospital pharmacy, military pharmacy or dispensary For 1 day €4,000 Additional days €2,000</p> <p>Pharmacy inspection based on documents €1,500</p> <p>Pharmacy inspection targeted at a single area of operations with duration of not more than 4 hours €2,000</p> <p>Inspection of a subsidiary pharmacy In connection with the main pharmacy inspection €2,000 As a separate inspection €3,000</p>	
<p>Inspection related to the approval or supervision of a GLP test laboratory, domestic For 1 day €4,000 Additional days €2,000</p> <p>Inspection related to the approval or supervision of a GLP test laboratory, abroad For 1 day €6,000 Additional days for each inspector €3,000</p>	
<p>A charge is payable for the following inspections if no inspection under the Medicines Act is carried out in connection with the inspection:</p> <p>Inspections carried out pursuant to narcotics legislation For 1 day €2,000 Additional days €1,000</p>	
<p>A charge is payable for the following inspections if no inspection under the Medicines Act is carried out in connection with the inspection:</p> <p>Mandatory reserve supply inspections For 1 day €2,000 Additional days €1,000</p>	
<p>Verification of the safety features of a medicinal product, repository system and repository system administrator</p>	€6,000

**8 ASSESSMENT AND FOLLOW-UP OF AGREEMENTS ON
CONDITIONAL REIMBURSEMENT OF A MEDICINAL PRODUCT**

Assessment report on the feasibility of conditional reimbursement agreement, for each medicinal product separately	€3,500
Assessment report on the implementation of conditional reimbursement agreement, for each medicinal product separately	€3,000
The fees include all pharmaceutical forms and/or strengths of the same trade name, provided that they are covered by the same conditional reimbursement agreement.	

**9 COPIES REPLACING THE ORIGINAL DECISION OR
CORRESPONDING DOCUMENT KEPT AT THE FINNISH MEDICINES
AGENCY**

For each commencing 10 pages	€7
For each commencing 10 pages subject to confidentiality of information	€12

**10 DECISIONS CONCERNING ACCESS TO DOCUMENTS OTHER THAN
THOSE UNDER SECTIONS 9 AND 11 OF THE ACT ON THE OPENNESS
OF GOVERNMENT ACTIVITIES**

Decisions concerning access to documents other than those under sections 9 and 11 of the Act on the Openness of Government Activities	€500
--	-------------